EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische StudieVergleichsstudieOpen Access

Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study

Rakesh Popat iD, Meral Beksac iD, Meletios A Dimopoulos iD, Moshe E Gatt iD, Francesca Gay iD, Jae-Cheol Jo iD, Prashant Kapoor iD, Eirini Katodritou iD, K Martin Kortüm iD, Silvia Ling iD, Chandramouli Nagarajan iD, Kenshi Suzuki und 16 weitere

Journal of Clinical Oncology · 20.01.2026 · 44 (3) · 164-175

DOI: 10.1200/jco-25-00924 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.01.2026. Verfasst von Rakesh Popat und 27 weiteren Autor:innen. Beteiligte Einrichtung: Haematology Department, University College London Hospitals NHS Foundation Trust, London, United Kingdom. Hauptthemen laut MEDLINE: Dexamethasone, Multiple Myeloma, Thalidomide, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Venetoclax, an oral BCL-2 inhibitor, has efficacy in t(11;14)-positive relapsed/refractory multiple myeloma (RRMM), which is enhanced by dexamethasone, which promotes BCL-2 dependency. METHODS The randomized, open-label, phase III CANOVA study (ClinicalTrials.gov identifier: NCT03539744 ) enrolled adults with t(11;14)-positive RRMM who had received ≥2 previous lines of therapy. Patients were randomly assigned (1:1) to venetoclax-dexamethasone or pomalidomide-dexamethasone until progression or intolerable toxicity. The primary end point was independent review committee assessed–progression-free survival (PFS) in the intention-to-treat population analyzed by stratified log-rank test (two-sided type I error rate, α = .05), with hazard ratio (HR) and 95% CI estimated by stratified Cox proportional hazard model. Secondary end points included response rates, overall survival (OS), minimal residual disease (MRD) negativity rate (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DexamethasoneMultiple MyelomaThalidomideAntineoplastic Combined Chemotherapy ProtocolsChromosomes, Human, Pair 14Translocation, GeneticChromosomes, Human, Pair 11HumansSulfonamidesFemaleMaleBridged Bicyclo Compounds, HeterocyclicMiddle AgedAgedAdultProgression-Free SurvivalAged, 80 and over

Substanzen

DexamethasonevenetoclaxpomalidomideSulfonamidesBridged Bicyclo Compounds, HeterocyclicThalidomide

Autor:innen und Institutionen

  • Haematology Department, University College London Hospitals NHS Foundation Trust, London, United Kingdom.
  • Department of Hematology, Ankara University, Ankara, Turkey.
  • Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
  • Department of Medicine, Korea University, Seoul, South Korea.
  • Department of Hematology, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
  • Division of Hematology 1, Department of Biotechnology and Health Science, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza, University of Torino, Torino, Italy.

ORCID-Profile: Rakesh Popat, Meral Beksac, Meletios A Dimopoulos, Moshe E Gatt, Francesca Gay, Jae-Cheol Jo, Prashant Kapoor, Eirini Katodritou, K Martin Kortüm, Silvia Ling, Chandramouli Nagarajan, Grace Ku, Monique Dail, Nizar J Bahlis, Shinsuke Iida, María-Victoria Mateos

Zitieren

APA

Popat, R., Beksac, M., Dimopoulos, M. A., Gatt, M. E., Gay, F., Jo, J. C., Kapoor, P., Katodritou, E., Kortüm, K. M., Ling, S., Nagarajan, C., Suzuki, K., Qiu, L., Onishi, M., Ku, G., Dail, M., Mukherjee, N., Ross, J. A., Badawi, M. A., …, & Mateos, M. V. (2026). Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study. Journal of Clinical Oncology, 44(3), 164-175. https://doi.org/10.1200/jco-25-00924

Vancouver

Popat R, Beksac M, Dimopoulos MA, Gatt ME, Gay F, Jo JC, et al. Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study. Journal of Clinical Oncology. 2026;44(3):164-175. doi:10.1200/jco-25-00924

BibTeX
@article{Popat2026,
  author = {Popat, Rakesh and Beksac, Meral and Dimopoulos, Meletios A and Gatt, Moshe E and Gay, Francesca and Jo, Jae-Cheol and Kapoor, Prashant and Katodritou, Eirini and Kortüm, K Martin and Ling, Silvia and Nagarajan, Chandramouli and Suzuki, Kenshi and Qiu, Lugui and Onishi, Maika and Ku, Grace and Dail, Monique and Mukherjee, Nabanita and Ross, Jeremy A and Badawi, Mohamed Ali and Fusco, Mary Jean and Dobkowska, Edyta and Arriola, Emma and Bueno, Orlando F and Bahlis, Nizar J and Iida, Shinsuke and Moreau, Philippe and Valent, Jason and Mateos, María-Victoria},
  title = {Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  volume = {44},
  number = {3},
  pages = {164--175},
  doi = {10.1200/jco-25-00924}
}
Kostenlos starten →